Sale!

Immunohistochemistry CD99 MIC2 Test

Original price was: $112.Current price is: $76.

-32%

The Immunohistochemistry CD99 MIC2 Test is a specialized diagnostic procedure used to detect the presence of CD99 antigen, which is highly expressed in Ewing sarcoma and peripheral neuroectodermal tumors. This test plays a crucial role in differentiating various types of small round blue cell tumors in cancer diagnosis. By identifying specific cellular markers, it helps pathologists and oncologists make accurate diagnoses and develop targeted treatment strategies. The test is particularly valuable for patients with suspected bone or soft tissue tumors, providing essential information for proper classification and management. At only $76 USD (regularly $112), this test offers affordable access to advanced cancer diagnostics across the United States.

Trusted Testing. Expert Care. Guaranteed Privacy.

  • Accredited and Trusted
  • Expert Scientists, Advanced Technology
  • Data Privacy Guaranteed
Guaranteed Safe Checkout

Immunohistochemistry CD99 MIC2 Test

Understanding the Immunohistochemistry CD99 MIC2 Test

The Immunohistochemistry CD99 MIC2 Test represents a cornerstone in modern cancer diagnostics, specifically designed to detect the presence of CD99 antigen expression in tissue samples. This sophisticated laboratory technique utilizes specialized antibodies to identify the MIC2 gene product, which serves as a crucial biomarker for several types of malignancies, particularly Ewing sarcoma family tumors.

What Does the CD99 MIC2 Test Measure?

This advanced diagnostic test specifically detects the expression of CD99 antigen, a transmembrane glycoprotein encoded by the MIC2 gene. The test measures:

  • Presence and intensity of CD99 antigen expression in tumor tissue
  • Pattern of cellular staining (membranous vs. cytoplasmic)
  • Percentage of positive tumor cells
  • Distribution of antigen expression throughout the tissue sample

Clinical Importance and Applications

The Immunohistochemistry CD99 MIC2 Test holds significant clinical importance in oncology practice. CD99 is highly expressed in approximately 95% of Ewing sarcoma cases and peripheral neuroectodermal tumors, making it an invaluable diagnostic marker. This test helps differentiate Ewing sarcoma from other small round blue cell tumors that may present with similar histological features but require different treatment approaches.

Who Should Consider This Test?

This test is recommended for patients presenting with:

  • Suspected bone or soft tissue tumors, particularly in children and young adults
  • Undifferentiated small round blue cell tumors requiring precise classification
  • Cases where Ewing sarcoma or peripheral neuroectodermal tumor is in the differential diagnosis
  • Patients with metastatic tumors of unknown primary origin showing small round cell morphology
  • Individuals with recurrent tumors requiring confirmation of diagnosis

Key Benefits of the CD99 MIC2 Test

Choosing the Immunohistochemistry CD99 MIC2 Test provides numerous advantages for patients and healthcare providers:

  • Accurate Diagnosis: Provides definitive identification of Ewing sarcoma and related tumors
  • Treatment Guidance: Helps oncologists develop targeted treatment strategies
  • Prognostic Information: Contributes to understanding disease behavior and potential outcomes
  • Differential Diagnosis: Distinguishes between similar-appearing tumors with different treatment requirements
  • Monitoring Response: Can be used to assess treatment effectiveness in follow-up biopsies

Understanding Your Test Results

Interpreting CD99 MIC2 test results requires specialized expertise from pathologists and oncologists:

Positive Results

A positive result typically shows strong membranous staining in tumor cells, suggesting:

  • High likelihood of Ewing sarcoma or peripheral neuroectodermal tumor
  • Need for additional confirmatory testing (such as molecular studies)
  • Consideration of specific treatment protocols for these tumor types

Negative Results

Negative staining may indicate:

  • Alternative diagnoses such as lymphoma, neuroblastoma, or rhabdomyosarcoma
  • Rare CD99-negative Ewing sarcoma cases
  • Need for additional immunohistochemical markers to establish diagnosis

Interpretation Considerations

It’s important to note that CD99 expression can occasionally occur in other tumors, and results should always be interpreted in the context of clinical presentation, imaging findings, and other laboratory tests.

Test Pricing and Availability

Test Name Discount Price Regular Price
Immunohistochemistry CD99 MIC2 Test $76 USD $112 USD

Turnaround Time and Sample Requirements

Our laboratory maintains efficient processing to ensure timely results:

  • Sample Acceptance: Daily by 6 PM
  • Report Timeline: Block: 5 days | Tissue Biopsy: 5 days | Tissue Large Complex: 7 days
  • Sample Type: Submit tumor tissue in 10% Formal-saline OR Formalin fixed paraffin embedded block
  • Shipping: Ship at room temperature

Pre-Test Instructions

For optimal results, please provide:

  • Copy of the Histopathology report
  • Site of biopsy information
  • Complete clinical history

Nationwide Availability

We have diagnostic centers conveniently located across the United States, serving patients in all major cities including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and many more. Our network ensures accessible, high-quality cancer diagnostics for patients nationwide.

Book Your Test Today

Take the first step toward accurate cancer diagnosis and personalized treatment planning. Our experienced team of pathologists and oncologists is ready to provide you with comprehensive diagnostic services and support.

Call or WhatsApp us today at +1(267) 388-9828 to schedule your Immunohistochemistry CD99 MIC2 Test and receive professional guidance throughout the diagnostic process.

Early and accurate diagnosis is crucial for successful cancer treatment outcomes. Trust our expertise in cancer diagnostics to provide you with the clarity and confidence needed for your healthcare journey.